Chemed (CHE) Releases Earnings Results, Beats Estimates By $0.05 EPS

Chemed (NYSE:CHE) released its earnings results on Wednesday. The company reported $2.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.05, Bloomberg Earnings reports. Chemed had a net margin of 8.49% and a return on equity of 30.54%. The company had revenue of $428.35 million for the quarter, compared to the consensus estimate of $423.83 million. During the same quarter in the previous year, the company earned $2.10 EPS. Chemed’s quarterly revenue was up 6.2% compared to the same quarter last year. Chemed updated its FY18 guidance to $10.60-10.85 EPS.

Shares of Chemed (CHE) traded up $4.35 during trading hours on Wednesday, reaching $253.73. 140,326 shares of the company’s stock were exchanged, compared to its average volume of 97,507. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48. The company has a market capitalization of $4,033.49, a price-to-earnings ratio of 56.38 and a beta of 1.13. Chemed has a 12-month low of $170.54 and a 12-month high of $275.83.

Several research analysts have weighed in on CHE shares. Royal Bank of Canada upped their target price on shares of Chemed to $232.00 and gave the stock a “sector perform” rating in a research note on Tuesday, October 31st. KeyCorp reiterated a “hold” rating on shares of Chemed in a research note on Friday, October 27th. TheStreet upgraded shares of Chemed from a “c+” rating to an “a-” rating in a research note on Friday, October 27th. Zacks Investment Research upgraded shares of Chemed from a “hold” rating to a “buy” rating and set a $251.00 target price for the company in a research note on Thursday, November 2nd. Finally, ValuEngine lowered shares of Chemed from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $236.00.

In related news, insider David Patrick Williams sold 11,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $241.28, for a total value of $2,654,080.00. Following the sale, the insider now directly owns 74,857 shares of the company’s stock, valued at $18,061,496.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Spencer S. Lee sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $238.24, for a total transaction of $238,240.00. Following the completion of the sale, the insider now directly owns 34,809 shares in the company, valued at $8,292,896.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,529 shares of company stock worth $3,741,746. Insiders own 4.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Chemed (CHE) Releases Earnings Results, Beats Estimates By $0.05 EPS” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/14/chemed-che-releases-earnings-results-beats-estimates-by-0-05-eps.html.

About Chemed

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Earnings History for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply